Prostate Cancer Imaging with [18Flourine]Prostate Specific Membrane Antigen (PSMA) PET: a study on pharmacokinetics and test repeatability - Pharmacokinetics and repeatability of [18F]PSMA

Vrije Universiteit Medisch Centrum0 个研究点目标入组 20 人开始时间: 待定最近更新: 2024年2月28日

适应症

试验速览

暂无简介。

•- Histologically proven prostate cancer, with lymphatic and/or haematogeneous metastases;
•- Written informed consent;
•- At least 2 metastases in the thorax per patient detected by conventional imaging (e.g., bone scan, either CT or MRI of the chest, abdomen and pelvis); conventional imaging should be recently performed (no longer than 3 months previous to the PET-CT scan);
•- At least one tumour (metastasis) with diameter * 1.5 cm (to minimize partial volume effects);
•- Patients able to remain supine for 60 minutes in the PET-CT scanner;;Part B;
•- Histologically proven prostate cancer, with lymphatic and/or haematogeneous metastases;
•- Written informed consent;
•- At least one tumour (metastasis) with diameter >1.5 cm detected by recently performed conventional imaging (maximal 3 months prior to the PET-CT scan);
•- Patients able to remain supine for 80 minutes in the PET-CT scanner;

•A potential subject who meets any of the following criteria will be excluded from participation in this study:
•- Claustrophobia (part A and B);
•- Multiple malignancies (part A and B);
•- Participation part A (Part B)

发起方